Related Experiment Videos
Antiproliferative effects of the enantiomers of flurbiprofen
J D McCracken1, W J Wechter, Y Liu
1Division of Gastroenterology, Loma Linda University Medical Center, California 92350, USA.
Abstract:
Nonsteroidal antiinflammatory drugs (NSAIDs) are recognized for inhibiting growth of colon tumors in animal models, and for reducing the risk of colon cancer in humans. The mechanisms involved have not been established, but are thought to be related to reduced prostaglandin biosynthesis. The present study investigates the effect of COX-inhibiting and non-COX-inhibiting enantiomers of flurbiprofen on rat colonocyte proliferation. Intestinal ulceration was used as a surrogate indicator of COX inhibition. Sprague Dawley rats were treated orally with 6.3 mg/kg of R- or s-flurbiprofen or vehicle. Colonocyte labeling index and small bowel ulcer index were measured. R-flurbiprofen and S-flurbiprofen significantly reduced colonocyte labeling index, by 34% and 23% respectively, compared with vehicle. R-flurbiprofen caused minimal ulcer formation (4.48 mm2) compared with S-flurbiprofen (94.4 mm2). These findings suggest that R-flurbiprofen-mediated control of colonocyte proliferation is independent of prostaglandin biosynthesis.
Insights
Nonsteroidal anti-inflammatory drugs (NSAIDs) can inhibit colon tumor growth. This study shows R-flurbiprofen controls colonocyte proliferation independently of prostaglandin synthesis, offering new insights into colon cancer prevention.
Area of Science:
- Oncology
- Pharmacology
- Gastroenterology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are linked to reduced colon cancer risk and tumor growth.
- Prostaglandin biosynthesis inhibition is a suspected mechanism for NSAID effects on colon cancer.
- The specific mechanisms of NSAID enantiomers on colonocytes remain unclear.
Purpose of the Study:
- To investigate the effects of R- and S-flurbiprofen enantiomers on rat colonocyte proliferation.
- To determine if colonocyte proliferation inhibition by flurbiprofen enantiomers is linked to prostaglandin synthesis (COX inhibition).
Main Methods:
- Sprague Dawley rats were administered R-flurbiprofen, S-flurbiprofen, or vehicle orally (6.3 mg/kg).
- Colonocyte proliferation was assessed via labeling index.
- Intestinal ulceration was measured as an indicator of COX inhibition.
Main Results:
- Both R- and S-flurbiprofen significantly reduced colonocyte labeling index (34% and 23%, respectively) compared to vehicle.
- R-flurbiprofen induced minimal intestinal ulceration (4.48 mm2) compared to S-flurbiprofen (94.4 mm2).
Conclusions:
- R-flurbiprofen effectively reduces colonocyte proliferation.
- The anti-proliferative effect of R-flurbiprofen on colonocytes appears to be independent of prostaglandin biosynthesis.
- These findings suggest novel therapeutic strategies for colon cancer prevention targeting non-prostaglandin pathways.